Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Insilico Medicine, an AI-driven drug discovery startup, has secured $110 million in funding, achieving unicorn status. The financing round was backed by Qiming Venture Partners and positions the company to advance its pipeline, particularly focusing on pivotal trials for its idiopathic pulmonary fibrosis (IPF) drug candidate, which has shown promising results in Phase 2 trials. Following this funding, Insilico is also considering a potential initial public offering (IPO) in Hong Kong. This development highlights the growing trend of AI startups in the biotech sector, which have increasingly attracted venture capital investment, with AI deals capturing nearly 50% of all VC funding in 2024.
🚀 AI Entrepreneurs: Week 101! 🎉 We’ve officially completed 100 weeks of breaking down AI’s biggest moves, startup wins, and billion-dollar deals. This issue: ⚡ The $100M reason AI startups fail 🔥 Nvidia’s rival Cerebras scales up 🤖 Google’s Gemini Robotics makes AI move ⚡…
🎉 101 Weeks of AI Breakthroughs! For nearly 2 years, AI Entrepreneurs has delivered the biggest AI news, tools & insights to fuel your success. 🚀 From AI in space to game-changing startups—this week’s issue is packed! Read now: https://t.co/0hZo102PVw https://t.co/eZyeQ14SNL
🚀 AI Entrepreneurs: Week 101! 🎉 We’ve officially completed 100 weeks of breaking down AI’s biggest moves, startup wins, and billion-dollar deals. This issue: ⚡ The $100M reason AI startups fail 🔥 Nvidia’s rival Cerebras scales up 🤖 Google’s Gemini Robotics makes AI move…
